Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alitretinoin for Chronic Hand Eczema: Multicenter Open-label Phase 4 Study (KCT0006687)
KCT0006687Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2022
- Countries
- 1
- Sponsor
- Daewoong Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Drugs
- alitretinoin
- Conditions
- chronic hand dermatitis (CHE)
01
Overview
Phase 4, open-label, single-arm trial of alitretinoin in chronic hand dermatitis (CHE), sponsored by Daewoong Pharmaceutical. Started Jan 2022; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Alitretinoin single-arm
All enrolled patients receive alitretinoin for chronic hand eczema in an open-label, real-world setting.
03
Who it enrols
Adult patients in Korea with chronic hand eczema receiving alitretinoin in routine clinical practice; healthy volunteers are not included.
Beyond the preview
Go deeper on KCT0006687.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006687.